By performing ChIP in Ptenpc−/− primary mouse prostate tumours, we demonstrated a 15-fold increase of Stat3 binding to the p19ARF promoter (Fig. 4h), which was abrogated in Ptenpc−/−Stat3pc−/− tumours. This evidence concerns the gene STAT3 and prostate neoplasm.